Donepezil in Treating Patients Who Have Undergone Radiation Therapy for Brain Tumors

Draft scope assessment: unclear. Attached because the study's own record describes metastatic disease. The study was not selected for this indication by its sponsor, and its eligibility has not been reconciled against this page in full. Found by searching ClinicalTrials.gov for this cancer type, restricted to studies that have posted results to the registry. No FDA notice, FDA label or NCI summary held by this site cites this study. Because the search asked for posted results, studies without posted results were never looked for, so their absence from this page means nothing.

Read the full study record and all posted results →

Linked outcomes

Measures are not ranked. Open each original source section for treatment groups, denominators, units and results.

primary · POSTED

Memory is quantified using the Hopkins Verbal Learning Test (HVLT) - immediate recall. Participants are asked to recall 12 words. Each recalled word is given one point. They are given three trials. The total score is the sum of the recalled words. The range for HVLT-Immediate recall is 0 to 36. Higher scores represent better memory.

Participants with 24 week HVLT data.

→

primary · POSTED

In the Hopkins Verbal Learning Test - discrimination, participants are given lists of 12 correct words and 12 incorrect words. HVLT-discrimination is the number of correctly recognized words minus the number incorrectly recognized. The range for this outcome measure is -12 to 12. Higher scores represent better memory.

Number of participants with 24 week memory data

→

Reported safety

Serious events are not the same as severe events. Compare the original safety groups and their at-risk populations.

Open the study safety table →

Quality of life and patient-reported measures

No linked quality-of-life measure is recorded for this setting and study.

Full draft applicability and source-link record

trial

release id: clinical-indications-draft-1
disease state id: ds-central-nervous-system-tumors-metastatic-2a1c1b0d
nct id: NCT00369785
trial label: Donepezil in Treating Patients Who Have Undergone Radiation Therapy for Brain Tumors
applicability: unclear
applicability note: Attached because the study's own record describes metastatic disease. The study was not selected for this indication by its sponsor, and its eligibility has not been reconciled against this page in full.
curation status: draft
reviewed by: Source null
reviewed at: Source null
created at: 2026-09-10T00:00:00Z
provenance class: registry-condition-search
discovery note: Found by searching ClinicalTrials.gov for this cancer type, restricted to studies that have posted results to the registry. No FDA notice, FDA label or NCI summary held by this site cites this study. Because the search asked for posted results, studies without posted results were never looked for, so their absence from this page means nothing.
outcome Count: 2
harms Count: 2
qol Count: 0

outcomes

release id
clinical-indications-draft-1
disease state id
ds-central-nervous-system-tumors-metastatic-2a1c1b0d
nct id
NCT00369785
outcome key
om-0000
source section id
NCT00369785-om-0000
source outcome index
0
endpoint
Memory as Quantified by HVLT-immediate Recall
endpoint definition
Memory is quantified using the Hopkins Verbal Learning Test (HVLT) - immediate recall. Participants are asked to recall 12 words. Each recalled word is given one point. They are given three trials. The total score is the sum of the recalled words. The range for HVLT-Immediate recall is 0 to 36. Higher scores represent better memory.
time origin
24 weeks
analysis role
primary
reporting status
POSTED
data cutoff
Source null
population note
Participants with 24 week HVLT data.
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
release id
clinical-indications-draft-1
disease state id
ds-central-nervous-system-tumors-metastatic-2a1c1b0d
nct id
NCT00369785
outcome key
om-0001
source section id
NCT00369785-om-0001
source outcome index
1
endpoint
Memory as Quantified by the HVLT-discrimination
endpoint definition
In the Hopkins Verbal Learning Test - discrimination, participants are given lists of 12 correct words and 12 incorrect words. HVLT-discrimination is the number of correctly recognized words minus the number incorrectly recognized. The range for this outcome measure is -12 to 12. Higher scores represent better memory.
time origin
24 weeks
analysis role
primary
reporting status
POSTED
data cutoff
Source null
population note
Number of participants with 24 week memory data
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z

arms

release id
clinical-indications-draft-1
disease state id
ds-central-nervous-system-tumors-metastatic-2a1c1b0d
nct id
NCT00369785
outcome key
om-0000
arm key
OG000
arm label
Arm I - Donepezil
regimen
Weeks 1-6: One 5 mg tablet orally donepezil hydrochloride Weeks 7-24: Two 5mg tablets per day donepezil hydrochloride: Weeks 1-6: One tablet Donepezil 5 mg given daily Weeks 7-24: Two Donepezil 5 mg tablets given daily
analyzed count
72
analyzed unit
Participants
is comparator
Source null
source pointer
NCT00369785-om-0000#groups/OG000
release id
clinical-indications-draft-1
disease state id
ds-central-nervous-system-tumors-metastatic-2a1c1b0d
nct id
NCT00369785
outcome key
om-0000
arm key
OG001
arm label
Arm II - Control
regimen
Weeks 1-6: One placebo tablet per day Weeks 7-24: Two placebo tablets per day Placebo: Weeks 1-6: One tablet per day Weeks 7-24: Two tablets per day
analyzed count
73
analyzed unit
Participants
is comparator
Source null
source pointer
NCT00369785-om-0000#groups/OG001
release id
clinical-indications-draft-1
disease state id
ds-central-nervous-system-tumors-metastatic-2a1c1b0d
nct id
NCT00369785
outcome key
om-0001
arm key
OG000
arm label
Arm I - Donepezil
regimen
Weeks 1-6: One 5 mg tablet orally donepezil hydrochloride Weeks 7-24: Two 5mg tablets per day donepezil hydrochloride: Weeks 1-6: One tablet Donepezil 5 mg given daily Weeks 7-24: Two Donepezil 5 mg tablets given daily
analyzed count
72
analyzed unit
Participants
is comparator
Source null
source pointer
NCT00369785-om-0001#groups/OG000
release id
clinical-indications-draft-1
disease state id
ds-central-nervous-system-tumors-metastatic-2a1c1b0d
nct id
NCT00369785
outcome key
om-0001
arm key
OG001
arm label
Arm II - Control
regimen
Weeks 1-6: One placebo tablet per day Weeks 7-24: Two placebo tablets per day Placebo: Weeks 1-6: One tablet per day Weeks 7-24: Two tablets per day
analyzed count
73
analyzed unit
Participants
is comparator
Source null
source pointer
NCT00369785-om-0001#groups/OG001

harms

release id
clinical-indications-draft-1
disease state id
ds-central-nervous-system-tumors-metastatic-2a1c1b0d
nct id
NCT00369785
harm key
EG000
source section id
NCT00369785-ae
event group key
EG000
event group label
Arm I - Donepezil
serious affected
12
serious at risk
96
other affected
88
other at risk
96
frequency threshold
5
collection period
24 weeks
event definition
Analysis includes everyone with post-treatment AE/toxicity data.
undenominated note
Source null
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
release id
clinical-indications-draft-1
disease state id
ds-central-nervous-system-tumors-metastatic-2a1c1b0d
nct id
NCT00369785
harm key
EG001
source section id
NCT00369785-ae
event group key
EG001
event group label
Arm II - Control
serious affected
10
serious at risk
92
other affected
80
other at risk
92
frequency threshold
5
collection period
24 weeks
event definition
Analysis includes everyone with post-treatment AE/toxicity data.
undenominated note
Source null
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z

quality of life

setting source links

Preserved source evidence · Not medical advice